EAU 2024: Bladder cancer latest
EAU 2024: Bladder cancer latest
Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Global trends and inequalities in breast cancer survival and care
Multiple myeloma in a resource constrained setting
Pembrolizumab a promising option for MIUC patients after radical surgery
ASCO GU 2024: Latest in PARP inhibitors for prostate cancer
Updates on lung cancer from WCLC and ESMO 2023
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems
Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis
Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC